key data for the use of fedratinib in mf
Published 4 years ago • 59 plays • Length 3:09Download video MP4
Download video MP3
Similar videos
-
5:10
fedratinib in mf: jakarta2 and freedom trials
-
1:40
fedratinib compared to ruxolitinib in the frontline setting for treatment of myelofibrosis
-
1:22
real-world outcomes of patients with mf treated with fedratinib post-ruxolitinib discontinuation
-
1:54
jakarta-2 reanalysis demonstrates activity with fedratinib in mf after ruxolitinib failure
-
1:12
dr. kuykendall on the approval of fedratinib in myelofibrosis
-
7:43
the role of fedratinib in myelofibrosis
-
1:26
updates on the use of momelotinib for the treatment of mf & clinical trials evaluating this agent
-
59:36
control myelofibrosis
-
52:14
fedramp process overview
-
1:04:22
key presentations on myeloproliferative neoplasms from recent major conferences
-
1:10
fedratinib reemerges as fda-approved treatment of myelofibrosis
-
1:06
fedratinib: mpn-associated myelofibrosis
-
1:16
indirect comparison of the safety of momelotinib vs fedratinib in patients with myelofibrosis
-
1:22
jakarta2 update: fedratinib in mf patients previously treated with ruxolitinib
-
1:29
evaluating the next steps for research in myelofibrosis
-
2:07
fedratinib for myelofibrosis
-
0:45
exploring fda-approved treatment options for patients with myelofibrosis
-
2:36
case 1: fedratinib treatment for myelofibrosis
-
4:12
pacritinib for patients with mf across the cytopenic spectrum
-
1:24
dr. mesa on current data with ruxolitinib and fedratinib in myelofibrosis
-
1:52
maic of momelotinib versus fedratinib safety in myelofibrosis
-
4:37
the use of ruxolitinib in mpn